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1. Introduction 
Kawasaki disease (KD), an  acute febrile mucotaneous lymph node syndrome, was initially 
described as a distinct clinical entity in 1967 by the Japanese physician, Dr Tomisaku 
Kawasaki (Kawasaki et al., 1974). Today the disease is recognized as an acute self - limited 
vasculitis of unknown etiology that predominantly affects young children of all racial and 
ethnic groups (Shulman et al., 1987). It is characterised by prolonged fever unresponsive to 
antibiotics, a polymorphous skin rash, erythema of the oral mucosa, lips and tongue, 
erythema of the palms and soles, bilateral conjunctival injection and cervical 
lymphadenopathy. This disease has become the leading cause of acquired heart disease 
among children in the developed world, with coronary artery aneurysms occurring in up to 
25% of untreated cases (Newburger & Fulton, 2004). 
2. Epidemiology 
Approximately 85% of children with KD are aged less than five years, with a relatively 
higher incidence reported for boys (Chang, 2002). Patients either younger than three months 
or older than five years are scarcely encountered and are regarded to be at a higher 
cardiovascular risk (Burns et al.,1986; Stockheim et al., 2000). Occurrence beyond late 
childhood is extremely rare. Less than 100 cases of adult KD have actually been reported in 
the world literature since the recognition of this illness, according to a 2010 case series and 
review of the disease in adults (Gomard – Mennesson et al., 2010; Wolff et al., 2007). In fact, 
many of the reported cases in adults have been misdiagnosed as KD, while the correct 
diagnosis was toxic shock syndrome ( Meissner & Leung 1995; Shulman et al., 1995).  
The epidemiology of KD is best documented in Japan, where regular nationwide 
epidemiological surveys are being conducted every two years since 1970. Based on the 
recent 20th  survey,  the number of patients with KD are continuously increasing, with an 
average annual incidence rate in 2007 and 2008 that reached 217/ 100.000 children younger 
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than five years of age, while the same value was 184.6/100.000 for the years 2005 and 2006 
(Nakamura et al., 2010, 2008).Over the past years, incidence figures have also been reported 
based on surveys upon hospital admission from Korea, Taiwan, the United States of 
America and the United Kingdom, enabling comparisons to be made. The highest incidence 
rate of KD per 100.000 children less than five years of age is recorded in Japan. Korea and 
Taiwan hold the second and third place respectively (Huang et al., 2009; Park et al., 2011 ). 
The United Kingdom and the United States are credited with a significantly lower annual 
incidence, which however, shows an increasing tendency over the past years (Harnden et 
al., 2002; Holman et al., 2010).  
A study performed from 1996 through 2001, showed that the annual incidence rate for KD 
among children younger than five years of age was 45.2 in Hawaii, the highest figure in the 
United States (Holman et al., 2005). Interestingly, the study showed that Japanese children 
in Hawaii were more likely to develop Kawasaki disease than children of other races in the 
same state or even children living in Japan. It is thus suggested that the incidence rate is 
higher in children either living in East Asia or being of Asian ancestry and living in other 
parts of the world. The overall prevalence in the United States is the highest among Asian 
and Pacific Islanders, intermediate in non-Hispanic African-Americans and the lowest for 
Caucasians (Holman et al., 2010a, 2010b). 
Other than the racial variations in the different geographical areas, a seasonal parameter in 
the distribution of KD cases also seems to exist. In most countries that hold records of KD 
occurrence, the greatest frequency is noted during winter months. In Japan, the disease 
shows a bimodal seasonality, that peaks once in January and secondly in June and July 
(Burns et al., 2005). Moreover, a bimodal pattern of occurrence is reported in Korea (Park et 
al., 2011). In Taiwan, recent studies have shown that KD is noted most frequently in the 
summer and least frequently in the winter (Huang et al., 2009). It is  therefore noticed that 
although the period may not always be the same, seasonal clustering of the disease does 
take place. Such seasonality and temporal occurrence suggest that infectious agents or other 
environmental factors that are yet unknown, might trigger the onset of the disease. 
The standardized mortality ratio associated with KD is 1,14 (Nakamura et al., 2008). There is 
a slightly increased mortality ratio in boys with the disease, which is mainly recorded 
during the acute phase and returns to baseline thereafter. This likely reflects the fact that 
cardiac and coronary artery abnormalities occur more frequently in boys than in girls and 
that most deaths related to KD are due to acute phase coronary disease or cardiac 
complications. In a study conducted in Japan, researchers have concluded that the mortality 
rate among males with cardiac lesions due to KD appeared to be higher than in the general 
population. Meanwhile, the mortality for girls with cardiac sequelae and for both male and 
female patients without sequelae, was not elevated (Nakamura et al., 2008). 
In a retrospective study we conducted in "P & A Kyriakou" Children's Hospital, a tertiary 
pediatric referral center in Athens, Greece, we retrieved thirty-four cases of KD within a 
period of 16 years (1989-2005). The age upon diagnosis was between 2 months to 11 years 
(average: 2.9 years) and there was no significant gender preference (18 girls versus 16 boys). 
The duration of hospitalization varied from 5 to 29 days depending on the severity of 
associated symptoms. Thirty two children were Greek and 2 were of Albanian origin. In 
regards to seasonality, 58.8% of the cases occurred between November and March of any 
given year as depicted in figure 1. 
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Fig. 1. Monthly distribution of the 34 cases hospitalized for Kawasaki disease in "P & A 
Kyriakou" Children's Hospital in Athens, Greece between the years 1989 and 2005 
3. Aetiology 
The cause of KD remains unknown. Most investigators suspect the existence of an infectious 
agent or the response to one or more pathogens to be responsible for the development of the 
disease. Evidence supporting this hypothesis includes the following: 
a. Seasonal clustering of KD during the winter months in most geographical areas (Burns 
et al, 2005). 
b. Geographical distribution of recorded periodic epidemics (Kao et al., 2008; Yanagawa et 
al., 1999). 
c. The fact that the disease occurs most often among toddlers, with only rare cases of 
infants younger than three years of age, which suggests the involvement of 
transplacental antibodies. Maternal immunoglobulin G may offer some protection to 
young infants and this protection diminishes as levels of maternal antibodies decrease 
(Burns & Glode, 2004). 
d. The 3–5 % of recurrency among cases in Japan, that may suggest either an aberrant 
immune response in this particular group of patients or the existence of more than one 
infectious agents responsible for the disease (Hirata et al., 2001). 
e. The clinical presentation of the disease with fever, cervical lymphadenitis, exanthema 
and conjunctivitis that resembles other infectious diseases such as scarlet fever and toxic 
shock syndrome (TSS).    
While the infectious agent hypothesis remains plausible, research on associating KD with a 
specific pathogen has been yet fruitless. A wide variety of microbiological and molecular 
methods have been employed in order to isolate pathogens from body fluidsand/or detect 
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agent – specific nucleic acids retrospectively, however with,limited results (Kawasaki et al., 
1974; Melish et al., 1976; Rowley et al., 1994). Although there have been numerous reports 
suggesting the involvement of infectious agents such as Parvovirus B19, Bocavirus, 
Cytomegalovirus or other viruses, Propionibacterium acnes, Rickettciae, and Yersiniae, none 
of these agents have been seen consistently isolated in children with KD (Catalano-Pons et 
al., 2007; Esper et al., 2005; Wang et al., 2004). Among the 34 cases of children hospitalized 
with KD in our study, some were examined for a variety of infectious agents as presented in 
table 1. Most of the children were tested negative for recent exposure to the tested infectious 
agents. Nevertheless, the small number of subjects tested and the lack of a control 
population precludes any definitive conclusions. 
 
 
Children 
tested 
% IgM (+) % IgM (-) % IgG (+) % IgG (-) 
EBV 16 - 100 12,5 87,5 
Parvo B19 10 - 100 30 70 
CMV 14 - 100 21,4 78,6 
Coxsackie - Virus 10 10 90 10 90 
 1 - 100 10 90 
 1 10 90 - 100 
ECHO - Virus 13 23 77 - - 
Table 1. Microbiological findings among the 34 cases of Kawasaki disease identified in "P & 
A Kyriakou" Children's Hospital, Second Department of Pediatrics, University of Athens, 
Greece during the period 1989-2005 
Due to the aforementioned clinical resemblance of KD with scarlet fever and TSS, it was 
suggested that superantigens, especially toxic shock syndrome toxin – 1 (TSST–1) and group 
A streptococcal exotoxins A, B and C (SPEA, SPEB, SPEC) may be involved in the 
pathogenesis of the disease (Table 2).  This was strongly supported by a study that reported 
associated increase of IgM antibodies against TSST–1, streptococcal pyogenic exotoxin A 
and staphylococcal enterotoxin A (Matsubara & Fukaya, 2007). However, an earlier 
multicentre, prospective study detected no difference in the isolation of superantigen-
producing bacteria between patients with the disease and febrile controls, thus complicating 
the matter further (Leung et al., 2002). On the other hand, bacterial toxins'-induced clonal 
expansion of T–cell receptors Vǃ2 and Vǃ8 is found among a subset of patients at the early 
stages of disease. This expansion seems to withdraw during the convalescent phase and 
may be responsible for the non specific T–cell activation that can lead to massive cytokine 
release and the development of KD (Abe et al.,1992; Brogan et al., 2008).  
Another hypothesis for the etiology of KD involves the implication of an environmental 
cause, such as pesticides, chemicals, heavy metals, toxins and pollutants. However, 
poisoning with environmental agents does not usually manifest acutely and is the result of 
chronic exposure. Nonetheless, some studies correlate KD to recent exposure to freshly 
shampooed carpets, habitation near a body of stagnant water and the use of a humidifier 
(Rauch et al., 1991; Treadwell et al., 2002). 
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Kawasaki 
disease 
Scarlet fever Toxic shock syndrome 
Age at onset <5 years of age >4 years of age 
90%  girls reaching the 
menstrual age 
Epidemic + + - 
Cause unknown 
A streptococcal 
pyrogenic exotoxin 
(SPE- A, B,C) 
Staphylococcus 
enterotoxin (TSST-1) 
Features of rash 
Polymorphous 
rash 
Diffuse erythema Diffuse erythema 
Conjunctival injection + _ + 
Labial and oral 
hyperemia 
Whole area 
Localized to 
pharynx, soft palate
Whole area 
Cervical 
lymphadenopathy 
+ + - 
Strawberry tongue + + + 
Erythema of the palms 
and soles 
+ + + 
Palmar desquamation + + + 
Recurrence 3 – 4 % rare 30,00% 
Shock or hypotension _ _ + 
Coronary arteriitis + _ _ 
Table 2. Comparison of clinical features of Kawasaki disease, Scarlet fever, and Toxic shock 
syndrome 
Other researchers have found evidence of an oligoclonal antibody response, suggesting  
that the disease is elicited by a conventional antigen rather than a superantigen (Rowley  
et al., 2001). 
The predilection of the disease for children either living in Asia or being of Asian ancestry as 
well as the relatively higher recurrence within families point towards a genetic 
predisposition for developing KD (Caquard et al., 2006; Uehara et al., 2003). In Japan, the 
relative risk of developing the disease among siblings is 10, and it reaches to 13 when 
referring to twins (Harada et al., 1986). Several studies have been conducted, trying to link 
susceptibility to KD or disease outcome to genetic polymorphisms (Ahn et al., 2003; Burns et 
al., 2005; Furuno et al., 2004; Sato et al., 2009). However, most of these studies have been 
carried out on single small cohorts of KD patients and findings were reported without 
validation in additional case–control studies. Other limitations include the small scale 
number of alleles examined, control and sample populations heterogeneity that complicates 
comparison and the existence of silent undiagnosed cases within the control group.  As 
opposed to candidate gene studies, genome–wide studies, which search for disease causing 
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mutations within the whole genome, seem very promising. One such recent study, has 
identified inositol 1,4,5-trisphosphate 3-kinase C (ITPK-C) gene as a susceptibility gene for 
KD (Onouchi et al., 2008). A functional single nucleotide polymorphism was recognized and 
associated with disease development but also with increased risk for the formation of 
coronary artery lesions. This polymorphism is shown to reduce splicing efficiency of ITPK-C 
mRNA. While ITPK-C is shown to act as a negative regulator of T-cell activation through the 
Ca2+/nuclear factor of activated T-cells signal pathway, the reduced splicing efficiency may 
contribute to immune hyperreactivity and thus the pathogenesis of KD (Onouchi, 2010). 
Further research on the biological significance of ITPK-C in other immune or non-immune 
cells may lead to better understanding of the disease pathogenesis. 
4. Pathology 
The histological findings of KD are consistent with those of a systemic vasculitis affecting 
medium sized arteries and veins to a lesser extent, with inflammatory lesions in virtually 
every organ. With the exception of arterial lesions, inflammatory lesions heal without 
residual changes (Amano et al., 1980; Masuda et al., 1986). Our understanding of the 
histopathological findings in KD is  restricted due to the scarcity of study material for 
reasons such as the low mortality rate and the difficulties encountered upon sampling 
medium sized arteries, especially coronary arteries.  
After the encounter of a genetically predisposed individual with the unknown trigger, an 
activation of mononuclear cells and platelets occurs (Jennette, 2002). The two latter cell 
populations interact with the endothelium that expresses surface adhesion molecules 
leading to margination of circulating cells, especially large mononuclear cells, lymphocytes 
and IgA plasma cells (Brown et al., 2001;Rowley et al., 2001). Activated endothelial cells also 
secrete monocyte chemoattractant protein 1 (MCP-1), which further attracts monocytes and 
vascular endothelial cell growth factor (VEGF), which increases vessel permeability (Asano 
& Ogawa, 2000; Maeno et al., 1998; Yasukawa et al., 2002) . Afterwards, platelets adhere to 
the vascular wall, while inflammatory cells cross the endothelium, gather in the intima, and 
liberate proinflammatory molecules such as interleukins, tumor necrosis factor ǂ (TNFǂ), 
and matrix metalloproteinases (MMP) (Eberhard et al., 1995; Gavin et al., 2003; Lin et al., 
1992). Neutrophils release neutrophil elastase which destroys the internal elastic lamina and 
contributes to disruption of the extracellular matrix. Active inflammation is succeeded by 
progressive fibrosis and finally scar formation. 
In the heart, perivasculitis and endarteritis of the three major coronary arteries are seen 
during the acute phase, followed by panvasculitis in the consequent two weeks period. 
Aneurysms, phlebitis, formation of intraluminal thrombi and potential pancarditis with 
lesions of the conduction system are also present during this phase of the disease. As the 
disease progresses, inflammation is replaced by granulation in the form of scarring, stenosis 
of major coronary arteries, fibrosis of the myocardium, coagulation necrosis, and 
endocardial fibroelastosis (Fujiwara & Hamashima, 1978). 
Inflammatory changes of the lungs, spleen, lymph nodes and salivary glands remain for 
more than 61 days from the onset of the disease, while in other organs these changes resolve 
much earlier. A predilection of KD for duct systems such as the prostate, pancreas, bile 
ducts and salivary glands has also been documented. However, in contrast to the 
irreversible changes that may occur in the cardiovascular system, histological changes on 
other parts of the body seem to fully recover after the convalescent phase of the disease 
(Amano et al., 1980). 
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The histological findings in KD strongly resemble polyarteriitis nodosa, and even though 
fine differences between the two illnesses do exist, differential diagnosis can only be made 
clinically. Most importantly, KD manifests with lymphadenopathy, which is usually absent 
in patients with polyarteritis nodosa (Jennette, 2002). 
5. Diagnosis & clinical features 
Signs and symptoms of KD develop over the first ten days of the illness and then gradually 
disappear spontaneously in most patients. In 20–25 % of the cases the disease is complicated 
by coronary artery lesions that may remain silent and diagnosed only years later, after the 
occurrence of a myocardial infarction episode  or sudden death (Burns et al., 1996; Kato et 
al., 1992). The disease may be separated in three phases according to its clinical presentation. 
The acute phase, which may last 7-14 days,  the sub-acute phase  from the 10th to the 24th 
day of the disease, and finally the convalescent phase, typically lasting 6-8 weeks. Diagnosis 
of the disease during the acute phase is of utmost significance, as treatment with high dose 
of intravenous immunoglobulin within the first 10 days of onset reduces the risk of coronary 
artery lesions (Newburger et al.,1986, 1991). However, diagnosis  of the disease is quite 
challenging, first because it remains clinically silent for some time, and secondly because 
there is no specific diagnostic test available. Aside from key elements of the history and 
physical examination, as well as indications based on laboratory markers of inflammation, 
the disease is presently diagnosed by the use of a case definition created for epidemiological 
surveys in Japan. The diagnostic criteria for complete and incomplete KD are presented in 
Table 3 and Table 4 respectively. 
 
a. Fever lasting for at least 5 days 
b. Presence of 4 of the following 5 conditions: 
1. Bilateral conjunctival injection 
2. Changes of the mucous membranes of the upper respiratory tract: injected 
pharynx, injected or/and dry fissured lips, strawberry tongue 
3. Polymorphous rash, primarily truncal.  
4. Changes of the extremities such as peripheral edema, peripheral erythema, and 
periungual desquamation. 
5. Cervical lymphadenopathy. 
c. Absence of any other reasonable explanation for the illness. 
Table 3. Diagnostic criteria for complete Kawasaki disease 
 
a. Fever lasting for at least 5 days. 
b. At least 2 of the 5 clinical criteria for Kawasaki disease (Table 3: B 1-5 ). 
c. Absence of any other sensible explanation for the illness. 
d. Laboratory findings, consistent with severe systemic inflammation. 
Table 4. Diagnostic criteria for incomplete/ atypical Kawasaki disease 
Although according to the criteria diagnosis requires a minimum of 5 days of fever, many 
experts prefer to treat classic KD earlier than the 5th day. The reason is that the case 
definition of KD is of questionable value as a clinical tool (Stapp & Marshall, 2002; Witt et 
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al.,1999). A broader definition of the disease would ensure identification of all patients who 
could benefit from intravenous immunoglobulin treatment. It is very common that the 
criteria for diagnosis of KD are not all present at the same time during the course of the 
illness (Newburger & Fulton, 2004). Patients with an inflammatory disorder that did not 
meet all the clinical criteria but with echocardiographic abnormalities of the coronary 
arteries have been identified. It should also been noted that 5 of the patients in Kawasaki' s 
original report of 50 patients did not fulfill the current criteria for the diagnosis of the 
disease (Burns, 2002). 
The lack of a specific and sensitive diagnostic test remains a great obstacle in the 
identification of all patients with KD. Besides the possibility that the illness may be 
underdiagnosed, there is an almost equally high chance that the disease is overdiagnosed 
since clinicians use non specific laboratory markers of inflammation to support their 
diagnosis.  Thus, differential diagnosis among diseases that require different treatment 
remains a challenge (Table 5). 
 
 Scarlet fever 
 Toxic shock syndrome (TSS) 
 Staphylococcal scalded skin syndrome (SSSS) 
  Measles and other febrile viral exanthems 
 Drug reactions  
 Steven – Johnson' s syndrome 
 Juvenile rheumatoid arthritis 
Table 5. Selected differential diagnosis of Kawasaki disease 
Acknowledgement of the protective role that early administration of intravenous 
immunoglobulin may play in the disease has placed a significant burden on clinicians to 
consider diagnosis in patients with unexplained fever with rash. Certain features of KD that 
may potentially deceive physicians include sterile pyuria misdiagnosed as urinary tract 
infection, cerebrospinal fluid (CSF) pleiocytosis misdiagnosed as aseptic meningitis, rash 
that may resemble a viral or drug side-effect sign, and cervical lymphadenopathy that is 
often confused with bacterial adenitis ( Dengler et al., 1998; Wu et al, 2005). 
The clinical symptoms upon presentation of the disease for the 34 hospitalized cases 
identified in our hospital between the years 1989 and 2005, are shown in Table 6. The 
predominant symptom was –as expected - fever with an average duration of 7,8 days. Other 
symptoms in decreasing order of frequency were rash, desquamation, conjunctivitis, 
lymphadenitis, fissured lips, glossitis, edema of the extremities, gastrointestinal 
abnormalities and arthritis. Aneurysms were identified in only 5 cases, and while 
tachycardia was absent in all cases, a 1st degree AV block was noted in 1 child. 
Laboratory indices at the time of entrance were suggestive of a generalized activation of the 
inflammatory system. Average white blood cell (WBC) count was 16.193 cells/μl, average 
erythrocyte sedimentation rate (ESR) was 74.7 mm, average level of C–reactive protein 
(CRP) was 120,2 mg/l and average platelet count was 45.700/μl. Liver transaminases 
(aspartate aminotransferase, AST and alanine aminotransferase, ALT) were elevated in only 
3 of the children. Urine analysis revealed the existence of aseptic pyuria in a 76,5% of the 
patients. An immune workup was performed for 10 of the children and is shown in Table 7. 
Finally, level of a1 – antithrypsin was tested in 3 cases and was found to be elevated in all 
three of them. 
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Clinical symptoms Number of patients % of patients 
1. fever 34 100 
2. rash 33 97,1 
3. desquamation 27 79,4 
4. conjunctivitis 26 76,5 
5. lymphadenitis 26 76,5 
6. fissured lips 26 76,5 
7. glossitis 14 41,2 
8. edema of the extremities 11 32,4 
9. aneurysms 5 14,7 
10. gastrointestinal abnormalities 5 14,7 
11. arrhythmia 1 2,9 
12. arthritis 1 2,9 
Table 6. Clinical presentation upon admission of the 34 cases of patients hospitalized for 
Kawasaki disease in "P & A Kyriakou" Children's Hospital in Athens, Greece between the 
years 1989 and 2005 
 
 
Number of patients 
with normal titer 
Number of patients 
with elevated titer 
Number of patients 
with decreased titer 
IgG 3 3 4 
IgM 3 7 - 
IgA 6 4 - 
Table 7. Immune workup of the  ten patients that underwent the examination in "P & A 
Kyriakou" Children's Hospital in Athens, Greece between the years 1989 and 2005. 
Even if the underlying cause remains unknown, there is an ever increasing need for the 
development of a unique diagnostic test that can help in identification of the disease. 
Although non specific markers of inflammation such as serum procalcitonin, interleukin–18 
(IL-18), WBC count, ESR, and CRP are all found elevated in KD, no association to the 
severity of the illness has yet been established (Mitani et al., 2005; Nomura et al., 2004; 
Okada et al., 2004). Unfortunately, the diagnosis of the disease currently depends largely on 
increased clinical awareness. 
6. Cardiovascular complications  
Kawasaki disease has become the leading cause of acquired heart disease among children in 
the developed world, even surpassing the impact of rheumatic fever in this respect. Twenty 
to 25% of untreated patients with KD develop coronary artery aneurysms and myocardial 
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infarction with an associated considerable morbidity and mortality (Taubert et al., 1994) . 
Other cardiovascular complications related with the disease include coronary artery 
stenosis, myocarditis, pericarditis with effusion and mitral valvulitis (Akagi et al.,1990; 
Dajani et al., 1993). Cardiac imaging is hence very important in the evaluation of patients 
with suspected KD. Echocardiography is both a sensitive and specific method to recognize 
coronary artery aneurysms in the acute and subacute phase of the disease (Yoshikawa et al., 
1979). Serial ultrasound studies can provide evidence of aneurysm formation, they may  
help evaluate left ventricular function as well as detect possible existence of pericardial 
effusion (McMorrow Tuohy et al.,2001; Scott et al., 1999). Doppler echocardiography  
can assist in the identification of mitral valve regurgitation and is also advisable in the 
presence of a pansystolic murmur upon auscultation. Morphological assessment of coronary 
arteries is of high significance, as the prognosis of aneurysms in patients with KD depends 
on the size and shape of the aneurysm. These features are best evaluated with three–
dimensional echocardiography (Miyashita et al., 2007). Coronary artery aneurysms are 
characterized as small if less than 5 mm in internal diameter, medium if 5–8 mm, or giant if 
larger than 8 mm (Dayani et al., 1993, 1994). Fusiform aneurysms with a diameter of  less 
than 8 mm have the best outcome, while giant aneurysms more than 8 mm have the worst. 
The latter is attributed to the fact that giant coronary aneurysms are highly probable to 
cause ischemic heart disease (Kamiya et al., 1995; Tatara & Kusakawa, 1987). On the 
contrary, small and medium diameter aneurysms have been reported to regress in 
approximately 50% of the cases and progress to stenosis in another 20% of patients (Kato et 
al., 1996). However, the value of echocardiographic detection of thrombi and coronary 
artery stenosis is questionable. In a selection of patients with KD, a series of other tests are 
recommended, aiming at better visualization of the coronary arteries. These include 
angiography, intravascular ultrasound, transesophageal echocardiography, magnetic 
resonance imaging, magnetic resonance angiography and ultrafast computed tomography 
(Greil et al., 2002; Naiser et al., 2008; Newburger et al., 2004; Suzuki et al., 1996). 
Interestingly, coronary artery lesions following KD may remain silent until the patient 
becomes 30 or even 40 years old. Especially patients without pathological findings in their 
echocardiogram during the acute and subacute phases of the disease usually remain 
clinically asymptomatic for at least a decade. To this end, a pediatric history of illness 
resembling KD should be sought in young adults presenting with myocardial infarction or 
sudden death ( Burns et al., 1996; Kato et al., 1992).  
Suggested risk factors for coronary artery formation include fever that endures even after 
intravenous immunogobulin administration, elevated CRP, low hemoglobin, 
thrombocytopenia, hypoalbuminemia, hyponatremia, male sex and age under one year ( 
Honkanen et al., 2003;  Koren et al., 1986; Mori et al., 2002). A proposed stratification of 
patients according to the relative risk for developing myocardial ischemia is presented, in table 
9 (Newburger et al.2004).  
7. Treatment 
7.1 Initial treatment 
Coronary artery aneurysms develop in 20 – 25% of patients left untreated. During the acute 
phase, the primary objective is to ascertain the diagnosis of the disease, provide supportive  
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Risk level 
Pharmacological 
therapy 
Follow – up & 
diagnostic tests 
Invasive tests 
1 (no coronary artery 
changes at any stage 
of illness) 
None beyond first 6–
8 weeks 
Cardiovascular risk 
assessment, 
counseling every 5 
years 
- 
2 (transient coronary 
artery ectasia 
disappears within 
first 6–8 weeks) 
None beyond first 6–
8 weeks 
Cardiovascular risk 
assessment, 
counseling every 3-5 
years 
- 
3 (1 small-to-medium 
coronary artery 
aneurysm/ major 
coronary artery) 
Low-dose aspirin (3–
5 mg/kg 
aspirin/day), at least 
until aneurysm 
regression is 
documented 
ECHO+ECG, 
cardiovascular risk 
assesment, 
counseling annually. 
Stress test/ 
evaluation of 
myocardial perfusion 
scan every 2 years 
Angiography, if 
noninvasive test 
suggests ischemia 
4 (1 large or giant 
coronary artery 
aneurysm, or 
multiple or complex 
aneurysms in the 
same coronary 
artery, without 
obstruction) 
Long-term 
antiplatelet therapy 
and 
warfarin (target INR 
2.0–2.5) or low-
molecular-weight 
heparin (target: 
antifactor Xa level 
0.5–1.0 U/ml) should 
be combined in giant 
aneurysms. 
ECHO+ECG twice 
annually. Stress test 
/evaluation of 
myocardial perfusion 
annually. 
First angiography at 
6–12 months or 
sooner if clinically 
indicated; repeated 
angiography if 
noninvasive test, 
clinical, or laboratory 
findings suggest 
ischemia; elective 
repeat angiography 
under some 
circumstances 
5 (coronary artery 
obstruction) 
Long-term low-dose 
aspirin. Warfarin or 
low-molecular-
weight heparin if 
giant aneurysm 
persists. Use of beta 
blockers to reduce 
myocardial O2 
consumption should 
also be considered 
ECHO+ECG twice 
annually. Stress test 
/evaluation of 
myocardial perfusion 
annually. 
Angiography 
recommended to 
address therapeutic 
options 
Table 9. Risk stratification for Kawasaki disease (ECHO: echocardiography, EKG 
electrocardiogram, INR: International normalized ratio) 
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care whenever needed (fluid and electrolytes), aim to attenuate the inflammatory process 
and prevent the formation of coronary artery aneurysms. Echocardiographic identification 
of coronary artery aneurysms not only redirects primary treatment plan, but also 
contributes to establishing the diagnosis of KD when there is absence of symptoms other 
than fever. It is thus suggested to consider echocardiography in a child with high fever of 
unknown etiology lasting more than 5 days and concurrent signs of generalized 
inflammation. 
Intravenous immunoglobulin G is the cornerstone of treatment for KD during the acute 
phase. Several studies have shown that intravenous immunoglobulin G administration early 
in the course of the disease (before the 10th day from fever onset) reduces total duration of 
clinical symptoms as well as the incidence of coronary artery aneurysms (Durongpisitkul et 
al., 1995; Furusho et al., 1984). It has been demonstrated that a single dose of 2 g/kg 
intravenous immunoglobulin G infused over 10–12 hours is more effective than multiple 
doses, and together with aspirin (Kato et al., 1996) now comprise the standard therapy in  
the USA, UK, Europe, Australia and many parts of Asia (Brogan et al., 2002). Although 
treatment should be instituted within the first ten days of illness, intravenous 
immunoglobulin G administration to children beyond the tenth day of illness is also 
recommended if they have either persistent fever without other explanation or aneurysms 
and ongoing systemic inflammation (Marasini et al., 1991; Newburger et al., 2004) . The 
molecular basis for the anti-inflammatory action  of intravenous immunoglobulin G is a 
field of extended research. Several mechanisms have been proposed including induction of 
immune inhibitory receptors such as FcǄIII on macrophages (Samuelsson et al., 2001), 
blocked interaction between endothelial and natural killer (NK) cells, necrosis-like changes 
in morphologic features of neutrophils (Sugita et al., 2005), accelerated apoptosis of 
circulating neutrophils (Tsujimoto et al, 2002) and down-regulation of genes expressed 
mainly by monocytes (Abe et al., 2005; Popper et al., 2007). Gamma globulin is a biological 
product manufactured from pooled donor plasma and adverse effects vary according to  
the product infused.  Generally, adverse effects are considered mild, comprising of 
headache, myalgia, fever, chills, backache, chest pain, nausea, vomiting, as well as increased 
plasma viscosity. These effects are usually self-limited, rarely demanding cessation of 
therapy, although slowing down of the infusion may be required (Rosenfeld et al., 1995) 
Live virus vaccines should not be administered to patients for at least eleven months 
following treatment, due to reduced immunogenicity related to passive antibodies in the 
infused product.  
Aspirin may also be administered in the acute phase of the disease in order to enhance the 
efficacy of intravenous immunoglobulin G. Currently, 80–100 mg/kg (divided in four doses) 
are administered in the acute inflammatory stage of the disease, while a single dose of 3–5 
mg/kg is given when patients have been afebrile for 3-7 days. Aspirin may be continued 
indefinitely in children that have already developed coronary artery abnormalities,. Despite 
the fact that aspirin has an important anti-inflammatory effect at high doses and an anti-
platelet action at low doses, it does not shorten the frequency of coronary artery aneurysm 
complications (Terai & Shulman, 1997). The latter, along with aspirin's adverse effects and 
the risk for developing Reye’s syndrome raise an important question regarding the value of 
exposing children with KD to high doses of aspirin.    
Corticosteroids are the golden standard in the treatment of other forms of vasculitis. 
Nevertheless, their use in children with KD is limited (Shulman, 2003) even though they are 
found to suppress markers of inflammation and decrease total fever duration (Nonaka  et 
al., 1995; Okada et al., 2003). 
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If initial therapy during the acute stage is successful, the primary objective at the subacute 
phase is to diminish platelet adhesion (usually by means of low dose aspirin 
administration), provision of supportive care when needed and monitoring patients in case 
of cardiovascular involvement. In both the subacute and convalescent phase, management 
plans are adjusted to coronary artery involvement and risk level, individualized for each 
patient (Newburger et al., 2004). 
For the 34 cases included in our study, treatment comprised primarily of intravenous 
immunoglobulin G and aspirin as shown on Table 10. Aspirin was administered to 31 
patients (91,2 %) during an average treatment duration of 5,7 days. Among children treated 
with aspirin, 23 continued with an antiplatelet dose (74,2%) after fever regression and only 1 
patient had to discontinue aspirin treatment due to related hepatotoxicity. Twenty eight 
patients were treated with Ǆ–globulin (82,4%) with an average treatment duration of 1,9 
days. Additional therapy consisted of penicillin in 2 children, carbamazepine that was later 
replaced by sorvitole in 1 child, clindamycin in 1 and finally a combination of ampicillin and 
netilmycin in another 1 of the children. In terms of patients' management, there was also a 
case admitted to the intensive care unit of the hospital due to sepsis and multiple organ 
failure. 
 
Treatment with various doses of aspirin 
dosage 
Number of patients treated 
with aspirin 
% of patients treated with 
aspirin 
5 mg/ kg 3 9,6 
60 mg/ kg 3 9,6 
80 mg/ kg 13 41,9 
85 mg/ kg 1 3,2 
100 mg/kg 11 35,5 
Treatment with intravenous immunoglobulin G 
dosage 
Number of patients treated 
with IVIG 
% of patients treated with 
IVIG 
1 g/ kg 2 3,6 
2 g/ kg 19 67,9 
400 mg/ kg/ 24 h 7 25 
Table 10. Treatment of the patients hospitalized for Kawasaki disease in "P & A Kyriakou" 
Children's Hospital in Athens, Greece between the years 1989 and 2005 
7.2 Treatment of persistent or recrudescent fever 
About 10–15% of children with KD that are treated with high dose aspirin and 2 g/kg 
intravenous immunoglobulin G will not become afebrile (Burns et al., 1998). Fever that is not  
reduced 36 hours after the completion of the initial intravenous immunoglobulin G infusion 
is defined as persistent or recrudescent fever. This subgroup, consisting of unresponsive to 
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intravenous immunoglobulin G patients, is proved to be at a higher risk for developing 
coronary artery aneurysms (Newburger, 2000). Unfortunately, no studies have yet proven 
the efficacy of a specific secondary treatment. Clinicians should first re-evaluate initial 
diagnosis and then move to selection of an appropriate secondary treatment. Most experts 
recommend re-treatment with intravenous immunoglobulin G, while plasmapheresis and 
treatment with corticosteroids, cyclophosphamide, methotrexate and monoclonal antibodies 
against TNF- ǂ have also been suggested (Ahn &Kim, 2005; Al Mayouf, 2004; Mori et al., 
1995; Weiss et al., 2004). 
7.3 Treatment of cardiovascular complications 
Treatment of coronary disease in patients with KD depends on the severity and extent of 
coronary involvement. Prevention of thrombosis and myointimal proliferation that leads to 
stenosis are the main objectives when managing patients with coronary aneurysms. Early 
coronary thrombosis occurs almost exclusively among patients with giant aneurysms 
(Takahashi, 1996). Unfortunately, no prospective data exist to guide clinicians towards the 
ideal plan; therefore, treatment of this subgroup of patients is still based on experts' 
recommendations. Prevention of thrombosis is accomplished by the administration of an 
antiplatelet or an anticoagulant agent, or most frequently by a combination of both. 
Antiplatelet agents play a significant role in managing patients at every stage of the disease, 
since platelet activation is a fundamental component of thrombosis development in KD 
(Burns et al., 1984, Kuramochi et al., 2000). Therefore, low dose aspirin (3–5 mg/kg daily) is 
the backbone of therapy for asymptomatic patients with mild and stable disease. Use of 
other antiplatelet agents (such as clopidogrel or dipyridamole) alone or combined with 
aspirin, may be more effective in suppressing platelet activation with more advanced 
coronary abnormalities (O'Brien et al., 2000). Randomized trials are needed to establish the 
role of low molecular heparin, monoclonal antibodies against IIB/IIIA receptor and 
warfarin in the long term management of patients with giant aneurysms (Brogan et al., 2002; 
Williams et al., 2002).  
In contrast to adult patients with aneurysms, the thrombus burden in children with KD is 
not related to the form of plaque instability and rupture (Kuramochi et al., 2000).  Hence, 
randomized controlled trials involving children with coronary thrombosis are needed to set 
up the role of thrombolytic medication (traditionally used in adults) such as streptokinase, 
urokinase and tisue plasminogen activator.  
Mechanical restoration of coronary blood flow is the other option in this group of patients 
that develop thrombosis. Coronary bypass grafting is the recommended surgical therapy 
upon evidence of reversible ischemia in stress imaging, if viable myocardium is present in 
the area of distribution of the affected vessel and when there is absence of coronary disease 
distal to the planned graft site (Kitamura et al., 1994). (Yoshikawa et al., 2000). Initially, the 
saphenous vein was used as the graft for this procedure; however, early failures in younger 
children led to the introduction of internal mammary arterial grafts (Kitamura et al., 1994). It 
was later found that patency rates of arterial grafts were higher as opposed to venal grafts. 
However, despite the encouraging results during the first decade after coronary artery 
bypass surgery, the arterial graft patency in later adult life is still unknown (Tsuda & 
Kitamura, 2004).  
Catheter intervention (such as balloon angioplasty, stent implantation, rotational ablation 
and transluminal coronary revascularization) is indicated in the presence of ischemic 
www.intechopen.com
Kawasaki Disease in  
a Tertiary Pediatric Referral Center in Athens, Greece and Review of the Literature 
 
345 
symptoms, reversible ischemia on stress testing and at least 75% stenosis of the left anterior 
descending coronary artery. Although the use of percutaneous coronary rotational ablation  
is still limited, this procedure may be the most appropriate catheter intervention for patients 
with KD. The advantage is the high success rate even among patients with calcified 
coronary artery stenoses (Ishii et al., 2002; Sugimura et al., 1997), which renders this method 
a potential therapeutic option also for postponing coronary artery bypass surgery (Lee et al., 
2005). Contraindications to catheter intervention include vessels with multiple, ostial, or 
long-segment lesions ( Akagi, 2011; Ishii et al., 2001). 
8. Conclusion 
Kawasaki disease is a systemic vasculitis of early childhood and comprises one of the 
leading causes of acquired heart disease in the western world. Although great efforts have 
been made in order to improve our understanding of the cause, pathogenesis and natural 
history of the disease, many of these aspects remain vague. Physical examination, laboratory 
markers of inflammation, and a case definition created for epidemiological surveys in Japan 
are the main tools currently available for the diagnosis of KD. Treatment with intravenous 
immunoglobulin in association with aspirin early in the course of the disease shortens the 
duration of symptoms and decreases the frequency of coronary artery abnormalities.  
During the period 1989–2005, 34 children with KD were admitted in our hospital. Analysis 
of different clinical manifestations and laboratory indices showed similar results to other 
studies. All children presented with fever, while the other most common symptoms were 
conjunctivitis, lymphadenitis, fissured lips and desquamation. Laboratory analyses were 
suggestive of non-specific inflammation.  Patients responded well to treatment with aspirin 
and Ǆ – globulin, and with the exception of one patient that was admitted to the intensive 
care unit, all other children did not develop any severe complications.  
Therapy of intravenous immunoglobulin-resistant KD remains obscure. What is the main 
concern, is the extent to which it is going to influence adult cardiovascular disease. Long 
term management of patients with KD is therefore very important and evidence–based 
approaches are required in order to define the best medical practice. Further research is also 
essential in elucidating the cause of the disease and developing high sensitivity and 
specificity diagnostic tests. 
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